Advertisement

Bausch + Lomb Corporation BLCO

Set alert

Price alert · BLCO

All alert types
20.00 USD -0.40 -1.96%

At close · Oct 30

20.00 0.00 0.00%

After hours · Oct 30, 5:05 PM ET

Bid
19.87 × 300
Ask
20.00 × 500
19.83 Day range 20.85
14.56 52-week range 20.40
YTD
+17.10%
1 year
+32.10%
Open
20.85
Prev close
20.40
Mkt cap
7.15B
Vol
1.43M
Avg vol
539.72K
EPS
-0.32
P/E
0.00
Div yield
0.00%
More statistics
Low
19.83
High
20.85
Forward P/E
16.72
Beta
0.00
Short ratio
5.12
Inst. own
11.24%
Dividend
0.00
Ex-div date
Earnings
Feb 17, 2027
50-d avg
17.29
200-d avg
16.66
1y target
21.64

3M chart

Chart tools
Interval

Events in this range
  • Sep 15, 2026Rating: Needham · Hold → Hold
  • Oct 7, 2026Rating: Barclays · — → Overweight
  • Oct 28, 2026Earnings: 0.34; estimate 0.2145; surprise 58.51%
  • Oct 29, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
  • Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
  • Oct 29, 2026Rating: Citigroup · Buy → Buy
  • Oct 29, 2026Rating: JP Morgan · Neutral → Neutral
Signals (28)
NameDateAgo
RSI: OverboughtOct 28, 20264 days ago
SMA: BullishOct 21, 20261 week ago
SMA: BullishOct 21, 20261 week ago
MACD: Buy SignalOct 21, 20261 week ago
SMA: BearishOct 12, 20262 weeks ago
SMA: BearishOct 12, 20262 weeks ago
MACD: Sell SignalOct 12, 20262 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BearishOct 8, 20263 weeks ago
SMA: BearishOct 8, 20263 weeks ago
SMA: BullishOct 7, 20263 weeks ago
MACD: Buy SignalOct 6, 20263 weeks ago
SMA: BullishOct 2, 20261 month ago
SMA: BearishSep 30, 20261 month ago
SMA: BullishSep 29, 20261 month ago
SMA: BearishSep 24, 20261 month ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BearishSep 17, 20261 month ago
SMA: BearishSep 15, 20261 month ago
MACD: Sell SignalSep 10, 20261 month ago
RSI: OverboughtSep 2, 20262 months ago
MACD: Buy SignalSep 1, 20262 months ago
MACD: Sell SignalAug 27, 20262 months ago
SMA: BullishAug 7, 20262 months ago
SMA: BearishAug 6, 20262 months ago

Key statistics

Market cap
7.14B
Enterprise value
0
Trailing P/E
0.00
Forward P/E
16.72
PEG ratio
0.89
Price / sales
1.32
Price / book
1.10
EPS (TTM)
-0.32
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-2.05%
Revenue (TTM)
5.42B
Revenue growth
7.30%
Free cash flow
0
Total cash
0
Total debt
0
Return on equity
0.00%
Shares outstanding
357.50M
Short % of float
5.55%
50-day average
17.29
200-day average
16.66

Analyst view

Consensus: buy

Buy
Price target (mean) 21.64 +8.2% upside
Target (low)
18.00
Target (mean)
21.64
Target (high)
26.00
Ratings (0m) 15 7 buy · 7 hold · 1 sell
  • Strong buy2
  • Buy5
  • Hold7
  • Sell0
  • Strong sell1

Next earnings

Feb 17, 2027

Expected Feb 17, 2027. Consensus EPS estimate 0.37246.

Earnings history

Financials — quick view

All financials
BLCO Revenue — quarterly 1.38B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
BLCO Net income — quarterly 32.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
BLCO EPS — quarterly 0.09
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

BLCO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 17, 2027Dec 30, 20260.35———
Oct 28, 2026Sep 30, 20260.21450.34+0.13+58.51%
Jul 29, 2026Jun 30, 20260.15440.16+0.01+3.63%
Apr 29, 2026Mar 31, 20260.060.08+0.02+33.33%
Feb 18, 2026Dec 31, 20250.350.32-0.03-8.57%
Oct 29, 2025Sep 30, 20250.160.18+0.02+12.50%

Upgrades / downgrades

BLCO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026JP MorganmainNeutralNeutral
Oct 29, 2026CitigroupmainBuyBuy
Oct 29, 2026RBC CapitalmainOutperformOutperform
Oct 29, 2026Wells FargomainEqual-WeightEqual-Weight
Oct 7, 2026Barclaysinit—Overweight
Sep 15, 2026NeedhamreitHoldHold

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Canada
Website
bausch.com

News

Your note

Sign in to keep a note on BLCO — it syncs with the Stock Master app.

Insider holders

BLCO insider holders
InsiderRelationLatest transactionDateShares held
BAILEY AMBROSE ROBERT DOUGLAS J.D.OfficerStock Award(Grant)Aug 4, 2026264,241
BERNIER NATHALIE DDirectorStock Award(Grant)May 25, 202685,505
BONNEFOY LUCOfficerStock Award(Grant)Aug 4, 2026103,801
ELDESSOUKY OSAMA AChief Financial OfficerStock Award(Grant)Aug 4, 2026393,527
ELDESSOUKY SAMChief Financial OfficerPurchaseMar 5, 2026407,130
HASHAD YEHIAOfficerStock Award(Grant)Aug 4, 2026187,350

Institution ownership

BLCO institution ownership
Holder% heldSharesValueReported
Icahn Carl C0.98%3,500,00069.86MJun 29, 2026
Deutsche Bank AG0.96%3,423,04668.32MJun 29, 2026
Oaktree Capital Management LP0.96%3,441,04268.68MJun 29, 2026
Shaw D.E. & Co., Inc.0.93%3,323,02166.33MJun 29, 2026
Davidson Kempner Capital Management LP0.88%3,158,97263.05MJun 29, 2026
Goldentree Asset Management LP0.74%2,660,50853.10MJun 29, 2026

Fund ownership

BLCO fund ownership
Holder% heldSharesValueReported
T. Rowe Price High Yield Fund, Inc.0.23%837,05016.71MAug 30, 2026
TR PRICE-Price (T.Rowe) U.S. High Yield Trust0.13%454,2209.07MJun 29, 2026
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd.0.06%204,4914.08MJun 29, 2026
T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F0.06%218,2114.36MAug 30, 2026
Unified Series Trust-BALLAST SMALL/MID CAP ETF0.04%147,8372.95MJun 29, 2026
Gabelli Healthcare & WellnessRx Trust0.04%144,0002.87MSep 29, 2026
Advertisement